Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis
| Autor: | Dariusz Jastrzębski, Joanna Warzecha, Aleksandra Gasiorek, Sylwia Czyz, Paulina Dębowska, Bettina Ziaja, Aleksandra Bełz, Dariusz Ziora, Dominika Galczynska |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
business.industry Pirfenidone Disease 030204 cardiovascular system & hematology Stage ii medicine.disease Mental health 03 medical and health sciences Idiopathic pulmonary fibrosis 0302 clinical medicine 030228 respiratory system Quality of life Internal medicine medicine Stage (cooking) business Progressive disease medicine.drug |
| Zdroj: | Idiopathic interstitial pneumonias. |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with poor prognosis. The aim of this study was to describe patients’ expectations of treatment and its relation to quality of life and stage in GAP Index. Answers were assessed by an original survey – patients were asked to choose 3 most important issues out of 15 mentioned. Quality of life was assessed by Short Form-36 Health Survey. A group of 40 patients, with median age of 72 years, has been qualified for treatment. Thirty one had stage I in GAP index, 9 others stage II. Patients’ expectations were following: good access to antifibrotic treatment (60%), extension of life regardless its quality (42%), good access to reference centers of IPF as well as maintenance of independence (both 39%). The expectations differed according to the stage of the disease - patients with stage GAP 2 preferred to have good access to reference centers of IPF contrary to those in early stage (GAP 1), for whom prolonging life, regardless its quality, was most crucial. In terms of the SF-36 questionnaire, patients with stage I in GAP index had greater score, although not statistically significant, in their physical functioning (PF; 43,58 vs. 34,96) and the role of limitations due to physical problems (RP; 39,1 vs. 29,31), than patients in stage II GAP group. The mean scores in Mental Health domains showed no significant differences between these groups. In conclusion, most of IPF patients expected a lot from pirfenidone treatment, regardless of side effects and proven results of such therapy. Our study highlights differences in expectations before treatment depending on stage of IPF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|